These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 21990319)

  • 1. Epithelial junction opener JO-1 improves monoclonal antibody therapy of cancer.
    Beyer I; van Rensburg R; Strauss R; Li Z; Wang H; Persson J; Yumul R; Feng Q; Song H; Bartek J; Fender P; Lieber A
    Cancer Res; 2011 Nov; 71(22):7080-90. PubMed ID: 21990319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Coadministration of epithelial junction opener JO-1 improves the efficacy and safety of chemotherapeutic drugs.
    Beyer I; Cao H; Persson J; Song H; Richter M; Feng Q; Yumul R; van Rensburg R; Li Z; Berenson R; Carter D; Roffler S; Drescher C; Lieber A
    Clin Cancer Res; 2012 Jun; 18(12):3340-51. PubMed ID: 22535153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overcoming physical barriers in cancer therapy.
    Beyer I; van Rensburg R; Lieber A
    Tissue Barriers; 2013 Jan; 1(1):e23647. PubMed ID: 24665377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multimerization of adenovirus serotype 3 fiber knob domains is required for efficient binding of virus to desmoglein 2 and subsequent opening of epithelial junctions.
    Wang H; Li Z; Yumul R; Lara S; Hemminki A; Fender P; Lieber A
    J Virol; 2011 Jul; 85(13):6390-402. PubMed ID: 21525338
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epithelial Junction Opener Improves Oncolytic Adenovirus Therapy in Mouse Tumor Models.
    Yumul R; Richter M; Lu ZZ; Saydaminova K; Wang H; Wang CH; Carter D; Lieber A
    Hum Gene Ther; 2016 Apr; 27(4):325-37. PubMed ID: 26993072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In pancreatic carcinoma, dual EGFR/HER2 targeting with cetuximab/trastuzumab is more effective than treatment with trastuzumab/erlotinib or lapatinib alone: implication of receptors' down-regulation and dimers' disruption.
    Larbouret C; Gaborit N; Chardès T; Coelho M; Campigna E; Bascoul-Mollevi C; Mach JP; Azria D; Robert B; Pèlegrin A
    Neoplasia; 2012 Feb; 14(2):121-30. PubMed ID: 22431920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Properties of Adenovirus Vectors with Increased Affinity to DSG2 and the Potential Benefits of Oncolytic Approaches and Gene Therapy.
    Bahlmann NA; Tsoukas RL; Erkens S; Wang H; Jönsson F; Aydin M; Naumova EA; Lieber A; Ehrhardt A; Zhang W
    Viruses; 2022 Aug; 14(8):. PubMed ID: 36016457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancement of the tumor penetration of monoclonal antibody by fusion of a neuropilin-targeting peptide improves the antitumor efficacy.
    Shin TH; Sung ES; Kim YJ; Kim KS; Kim SH; Kim SK; Lee YD; Kim YS
    Mol Cancer Ther; 2014 Mar; 13(3):651-61. PubMed ID: 24435448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical safety and efficacy studies with an affinity-enhanced epithelial junction opener and PEGylated liposomal doxorubicin.
    Richter M; Yumul R; Wang H; Saydaminova K; Ho M; May D; Baldessari A; Gough M; Drescher C; Urban N; Roffler S; Zubieta C; Carter D; Fender P; Lieber A
    Mol Ther Methods Clin Dev; 2015; 2():15005. PubMed ID: 26029716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intracellular Signaling and Desmoglein 2 Shedding Triggered by Human Adenoviruses Ad3, Ad14, and Ad14P1.
    Wang H; Ducournau C; Saydaminova K; Richter M; Yumul R; Ho M; Carter D; Zubieta C; Fender P; Lieber A
    J Virol; 2015 Nov; 89(21):10841-59. PubMed ID: 26292319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity of rat-neu
    Sow HS; Benonisson H; Brouwers C; Linssen MM; Camps M; Breukel C; Claassens J; van Hall T; Ossendorp F; Fransen MF; Verbeek JS
    Sci Rep; 2020 Mar; 10(1):3933. PubMed ID: 32127568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The vitamin E analog, alpha-tocopheryloxyacetic acid enhances the anti-tumor activity of trastuzumab against HER2/neu-expressing breast cancer.
    Hahn T; Bradley-Dunlop DJ; Hurley LH; Von-Hoff D; Gately S; Mary DL; Lu H; Penichet ML; Besselsen DG; Cole BB; Meeuwsen T; Walker E; Akporiaye ET
    BMC Cancer; 2011 Nov; 11():471. PubMed ID: 22044845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Junction opener protein increases nanoparticle accumulation in solid tumors.
    Wang CE; Yumul RC; Lin J; Cheng Y; Lieber A; Pun SH
    J Control Release; 2018 Feb; 272():9-16. PubMed ID: 29305923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural and functional studies on the interaction of adenovirus fiber knobs and desmoglein 2.
    Wang H; Yumul R; Cao H; Ran L; Fan X; Richter M; Epstein F; Gralow J; Zubieta C; Fender P; Lieber A
    J Virol; 2013 Nov; 87(21):11346-62. PubMed ID: 23946456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14.
    Wang H; Li ZY; Liu Y; Persson J; Beyer I; Möller T; Koyuncu D; Drescher MR; Strauss R; Zhang XB; Wahl JK; Urban N; Drescher C; Hemminki A; Fender P; Lieber A
    Nat Med; 2011 Jan; 17(1):96-104. PubMed ID: 21151137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor-associated hyaluronan limits efficacy of monoclonal antibody therapy.
    Singha NC; Nekoroski T; Zhao C; Symons R; Jiang P; Frost GI; Huang Z; Shepard HM
    Mol Cancer Ther; 2015 Feb; 14(2):523-32. PubMed ID: 25512619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plant-made trastuzumab (herceptin) inhibits HER2/Neu+ cell proliferation and retards tumor growth.
    Komarova TV; Kosorukov VS; Frolova OY; Petrunia IV; Skrypnik KA; Gleba YY; Dorokhov YL
    PLoS One; 2011 Mar; 6(3):e17541. PubMed ID: 21390232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neural stem cells as a novel platform for tumor-specific delivery of therapeutic antibodies.
    Frank RT; Edmiston M; Kendall SE; Najbauer J; Cheung CW; Kassa T; Metz MZ; Kim SU; Glackin CA; Wu AM; Yazaki PJ; Aboody KS
    PLoS One; 2009 Dec; 4(12):e8314. PubMed ID: 20016813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Controlled extracellular matrix degradation in breast cancer tumors improves therapy by trastuzumab.
    Beyer I; Li Z; Persson J; Liu Y; van Rensburg R; Yumul R; Zhang XB; Hung MC; Lieber A
    Mol Ther; 2011 Mar; 19(3):479-89. PubMed ID: 21081901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-epidermal growth factor receptor monoclonal antibody cetuximab inhibits EGFR/HER-2 heterodimerization and activation.
    Patel D; Bassi R; Hooper A; Prewett M; Hicklin DJ; Kang X
    Int J Oncol; 2009 Jan; 34(1):25-32. PubMed ID: 19082474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.